title: Neutralization of the oedematogenic activity of Bothrops jararaca venom on the mouse paw by an antibothropic fraction isolated from opossum (Didelphis marsupialis) serum.
abstract: The pharmacological modulation of mice paw oedema produced by Bothrops jararaca venom (BJV) has been studied. Intraplantar injection of BJV (1-30 micrograms/paw) produced a dose- and time-related oedema, which was maximal 30 min after injection, reduced gradually thereafter and disappeared over 48 h. BJV heated at 100 degrees C for 5 or 15 min blocked local hemorrhage and caused partial inhibition of its oedematogenic activity. The BJV oedema was not inhibited by the anti-histamine meclizine, the inhibitor of histamine and serotonin, cyproheptadine, PAF-acether antagonist WEB 2170 or by the anti-leukotrienes C4/D4, LY 171883. Dexamethasone, aspirin, indomethacin, and the dual cyclooxygenase and lipoxygenase inhibitor BW 755C inhibited BJV-induced oedema indicating that arachidonic acid metabolism products via the cyclooxygenase pathway participate in its genesis and/or maintenance. The antibothropic fraction (ABF) (25-200 micrograms/paw) isolated from Didelphis marsupialis serum neutralized the oedema induced by the venom with and without heating, the hemorrhage induced by BJV and partially blocked the oedema induced by bradykinin and by cellulose sulphate. The oedema produced by histamine, serotonin, PAF-acether or leukotriene C4 was not inhibited.
authors.affiliation: Departamento de Bioquímica, Universidad Centro Occidental, Barquisimeto, Venezuela.
authors.forename: J
authors.initials: J
authors.lastname: Perales
authors.forename: C Z
authors.initials: CZ
authors.lastname: Amorim
authors.forename: S L
authors.initials: SL
authors.lastname: Rocha
authors.forename: G B
authors.initials: GB
authors.lastname: Domont
authors.forename: H
authors.initials: H
authors.lastname: Moussatché
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology; D000997:Antivenins / Q000302:isolation & purification / Q000494:pharmacology*; D003435:Crotalid Venoms / Q000276:immunology* / Q000633:toxicity; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D004487:Edema / Q000139:chemically induced / Q000517:prevention & control*; D005528:Foot / Q000473:pathology; D006633:Histamine Antagonists / Q000494:pharmacology; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology; D008297:Male; D051379:Mice; D009893:Opossums / Q000276:immunology*; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors; D013256:Steroids
chemical_list: D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000997:Antivenins; D003435:Crotalid Venoms; D016861:Cyclooxygenase Inhibitors; D006633:Histamine Antagonists; D016859:Lipoxygenase Inhibitors; D010972:Platelet Activating Factor; D013256:Steroids